experimental drugs

Insmed halts development of its drug Iplex for MMD1 and ALS, at least for now

Posted on Thursday, July 30, 2009 - 10:32, By: ALSN Staff
The Richmond, Va., biopharmaceutical company Insmed announced July 27, 2009, that it will not supply its experimental drug Iplex to any new patients with amyotrophic lateral sclerosis (ALS) for the foreseeable future, and that it intends to analyze the available data on Iplex for ALS and type 1...